Myriad retains rights to cardiovascular gene tests under $60 mil. deal with Ciba-Geigy.
This article was originally published in The Gray Sheet
Executive Summary
CIBA-GEIGY's $60 MIL. AGREEMENT WITH MYRIAD GENETICS for cardiovascular gene discovery involves $32 mil. in equity and research funding in the Salt Lake City molecular genetics firm. The equity represents less than a 10% interest in Myriad.